

Industry-academia-collaboration to foster innovation in field of nutra and wellness

20 May 2022 | Views

Zeon, an end-to-end researched-driven preferred manufacturing partner for nutraceutical, ayurvedic, immunity boosters etc, is into manufacturing and developmental solutions to meet the ever-changing market demand. Suresh Garg, MD & Co-Founder, Zeon Lifesciences in interaction with Bio Spectrum India, gives insight into the company's plans and how industry-academia collaboration will help in R&D related activities



Recently you have signed an MoU with Delhi Pharmaceutical Sciences & Research University for R&D. Do you plan to go in for more such collaborations with other institutes for R&D-related activities?

We are in continual planning for more collaboration with universities that are focused on the area of Nutraceutical and Wellness Research (Scalable and sustainable technologies). We strongly believe in industry-academia-collaboration to foster innovation in the field of Nutra and Wellness for socio-economic benefits.

What will be your new offerings in the finished formulations, ingredients, and nutraceuticals market?

We as Zeon work on various formulations including tablets, two-piece capsules, dry blended powders, spray dried powders, diskettes, liquids, shots, RTM powders etc. for different therapeutic benefits. We also enhance our capability in developing products under medical nutrition. We also working on innovative packaging technologies to cater competitive market. We have one arm called 'Biosys' under which working on various value-added ingredients for synergising our formulations.

Which new technologies have you incorporated into the facility to produce formulations, ingredients, etc?

We are working on encapsulation technologies for enhancement of bioavailability and efficacy which could impart into the formulation for better efficacy. We also working on to nanonisation of various products. Recently incorporated Sublingual spray's into our portfolio which are patented and clinically proven for efficacy and patient compliance.

Your investment strategy for the next five years.

We are in the continual expansion of the facility to enhance capacity as well as the incorporation of joint ventures with various companies for innovative products.

Any plans to set up a new facility apart from Paonta Sahib?

Yes, we are open to the opportunity to set up a plant apart from Paonta.

How much revenue did the company generate in the last fiscal and what will be your expectations?

During the last fiscal year, the company has achieved approx Rs 230 crore and for next year we are aiming to achieve Rs 400 Crore.

Tell us about your global collaborations:

We are already in collaboration with Optibiotix UK and Vitonnix UK. Already in discussion with more companies. We strongly believe in the in-licensing of innovative and clinically proven ingredients/technologies which could upper edge Zeon.

What will be your plans in the life sciences space in 2022 and beyond?

We are certainly interested to work in the area of fermentation technologies and are in discussion with some of our collaborators.

Sanjiv Das
sanjiv.das@mmactiv.com